Skip to main content

Table 3 Inflammatory cytokines, C-reactive protein, erythrocyte sedimentation rate, and rheumatoid factor before and after 30 day treatment

From: Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis

  Placebo group (n = 14) B6 group (n = 14) p value (baseline)a p value (treat)b
  Before After Before After   
PBMC IL-6 (pg/ml)c 490 (289–832) 1,369 (202–1,665) 1,112 (437–1,352) 1,476 (918–1,602) 0.698 0.315
PBMC TNF-α (ng/ml)d 224.6 (118.4–361.8) 341.5 (242.6–654.1) 114.1 (319.1–89.2) 178.7 (59.6–391.0) 0.320 0.963
Serum TNF-α (pg/ml) 1.7 (0.7–3.8) 2.1(0.3–5.5) 1.5 (0.9–2.7) 2.0 (0.9–3.6) 0.134 0.166
Serum CRP (mg/l) 13.0 (5.90–27.6) 7.0 (4.4–27.5) 2.0 (0.1–17.2) 3.0 (0.6–14.8) 0.387 <0.0001
ESR 31.0 (19.4–52.6) 32.0 (24.0–49.7) 27.5 (18.8–41.6) 31.0 (22.4–38.9) 0.425 <0.0001
RF (IU/ml) 72.0 (43.3–131.2) 93.8 (37.1–132.5) 76.4 (47.5–130.0) 73.8 (47.3–122.8) 0.697 <0.0001
  1. Data are presented as median (95% CI). aEffects of each baseline (before treatment) value on its post-treatment outcome. bTreatment effects (placebo versus vitamin B6) were examined by analysis of covariance, adjusting for baseline (before) value. cSpontaneous production of IL-6 by peripheral blood mononuclear cells (PBMCs). dSpontaneous production of tumor necrosis factor (TNF)-α by PBMCs. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor.